In the News
June 20, 2019
House Passes Four-Bill Appropriations Package June 19, 2019 - $982.8 billion package invests For the People, with robust funding for...Read More
May 7, 2019
immuno-oncologynews.com/2019/04/30/keytruda-inlyta-combo-approved-fda-untreated-advanced-kidney-cancer/Ines Martins, PhDApril 30, 2019 The U.S. Food and Drug Administration (FDA) has approved a combination of Keytruda (pembrolizumab) plusInlyta (axitinib) for the initial treatment...Read More
Funded major projects to date include:
RADVAX investigator led immunotherapy trial for 25 advanced kidney cancer patients at UT Southwestern combining Nivolumab, Ipilimumab and SBRT.
Support of UT Southwestern’s Kidney Cancer Research Program. 1 of only 2 SPOREs (Specialized Programs of Research Excellence) for Kidney Cancer in the US.
Our primary sources of support are donations from the general public and fundraising.
Stay in Touch: Join The Kidney Cancer Coalition Email List!
Please enter your information below: